Editorial: antigenic response to CT ‐P13 and infliximab originator in IBD shows similar epitope recognition—evidence from basic science supports safe switching to biosimilars. Authors’ reply

Alimentary Pharmacology&Therapeutics,Volume 48, Issue 5, Page 575-576, September 2018.

Source: Alimentary Pharmacology and Therapeutics - August 10, 2018 Category: Drugs & Pharmacology Authors: J. Goncalves , F. Magro , S. Danese , P. L. Lakatos , S. Ben ‐Horin Source Type: research